Tier 4 — mechanistic
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity (Fisetin HIGH)
Not applicable - trial registered on ClinicalTrials.gov (not yet published in a peer-reviewed journal)
2024
Not applicable (trial registry record, no journal volume/issue/pages)
Bibliography
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- ClinicalTrials.gov lead sponsor/responsible party: Ove Andersen, Hvidovre University Hospital. Collaborators: University of Southern Denmark and Mayo Clinic.
- Competing interests
- Not disclosed in the ClinicalTrials.gov registry record; no funding-source conflicts are indicated.
Study snapshot
| Design | Randomised, parallel-group, quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled Phase 1/2 interventional trial. |
|---|---|
| Model | Human participants: healthy volunteers and older patients with multimorbidity. |
| Sample | Planned enrollment: 60 participants. |
| Intervention | Oral fisetin versus placebo, administered for two days, with follow-up assessments at regular intervals for up to three months. |
| Duration | Two-day dosing period with follow-up to approximately 3 months (day 84); estimated study start 2026-03-24, primary completion and full completion both estimated 2028-12-31 (registry data). |
| Endpoints | Population-based pharmacokinetic (popPK) model for fisetin and its metabolites; Adverse events and symptoms/vital sign changes; Soluble urokinase plasminogen activator receptor (suPAR) and other SASP/inflammation markers; Senescence markers (p16INK4a, p21CIP1/WAF1, SA-beta-gal) in immune cells and tissue biopsies; Senolysis markers and aging markers (alpha-klotho, FGF21); Frailty indices, physical function, cognitive function (MoCA, DSST) and quality of life (EQ-5D-5L) |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Fisetin Senolytic: Does It Clear Senescent Cells in Humans?Fisetin is clearly senolytic in some experimental cell systems and strongly senotherapeutic in animals, but controlled proof of systemic senescent-cell clearance in...Read analysis
- Fisetin Benefits: What the Evidence Actually ShowsFisetin has strong preclinical evidence as a senotherapeutic, but human findings remain early and mixed. This evidence review separates randomized trials, human...Read analysis
- Fisetin Dosage: What Human Studies Actually UseThere is no single established fisetin dose. Human studies have used 100 mg/day, 200–800 mg/day, 2 mg/kg intermittent dosing, ~20 mg/kg senolytic...Read analysis
- Fisetin: A Clinician's Guide to Evidence, Dose & SafetyFisetin is a plant flavonol with senolytic activity in selected cell and animal models. Human research now spans continuous low-dose regimens, intermittent...Read analysis
- Fisetin Pulse Dosing: What Human Trials Actually UseThere is no single Mayo Clinic fisetin protocol. Human trials use one-, two- and three-day pulses, with repeat intervals ranging from one...Read analysis
- Best Fisetin Supplement (2026): The Complete Buyer's GuideCompare ten fisetin supplements on ingredient transparency, batch testing, formulation and dose format, with US/UK/Canada purchasing considerations. DoNotAge Pure Fisetin is our...Read analysis
- Fisetin for Muscle Preservation and Frailty: The Evidence (2026)A 2025 mouse study linked intermittent fisetin with better physical function and lower skeletal-muscle senescence markers in aged mice. Human studies are...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
